ITOS240719P6000
- 0.20
- 0.000.00%
ITeos Therapeutics Newsroom
ITeos Therapeutics Doses First Patient in Phase 3 Trial of Belrestotug With Dostarlimab; Triggers $35 Million GSK Payment
iTeos Therapeutics (ITOS) said Monday it has dosed the first patient in its phase 3 trial of belrestotug with dostarlimab, triggering a $35 million development milestone payment from its belrestotug p
Express News | Iteos Announces First Patient Dosed in Galaxies Lung-301 Phase 3 Study, Earning $35 Million in Milestones From GSK
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks were rising Friday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) gained 0.4%.
ITeos, Arcus Shares Drop After Genentech's Lung Cancer Study Misses Endpoints
iTeos Therapeutics (ITOS) and Arcus Biosciences (RCUS) shares fell in early Friday trading after Roche Group's Genentech said its phase 2/3 non-small cell lung cancer study failed to meet its primary
Express News | Shares of Compugen Down 3%, Iteos Therapeutics Down 6.1%, and Arcus Biosciences Down 3.8%
Express News | Anti-Tigit Drugmakers Fall as Roche's Lung Cancer Drug Fails Trial
Roche's TIGIT therapy failed to achieve its main goal. Biotechnology stocks like Compugen (CGEN.US) suffered heavy losses before the market opened.
On Friday, following the failure of a similar drug being developed by Swiss pharmaceutical giant Roche in phase 2/3 clinical trials, the stock prices of some biotech companies developing a new type of anti-cancer drug (known as a new "anti-TIGIT therapy") have fallen significantly in pre-market trading. Roche's stock price also fell in the European stock market on Thursday. Earlier, the company stated that tiragolumab, its anti-TIGIT treatment drug as part of a frontline drug combination, was used in the SKYSCRAPER study for non-squamous non-small-cell lung cancer.
Roche's Setback in Lung Cancer Trial Sends Anti-TIGIT Developers Lower
Express News | Iteos and GSK Initiate Galaxies Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic Pd-L1 Selected Non-Small Cell Lung Cancer
J.P. Morgan Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
J.P. Morgan analyst Brian Cheng maintains $ITeos Therapeutics(ITOS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 31.2% and a total average return of -18.7% over
We Think ITeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights iTeos Therapeutics to hold its Annual General Meeting on 11th of June Total pay for CEO Michel Detheux includes US$578.9k salary The total compensation is 38% higher than the average
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Raises Price Target to $46
ITeos Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 156.98% HC Wainwright & Co. $44 → $46 Maintains Buy 03/12/2024 50.84% JP Morgan $29 → $27 Maint
ITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment Data
By Ben Glickman Shares of iTeos Therapeutics rose sharply after the company said one of its tumor treatment clinical trials had shown promising interim results. The stock was up 47% to $17.86 in Fri
Riding High: ITeos Therapeutics' (ITOS) Stock Surges Amid Market Activity
Following the dissemination of a corporate update and financial appraisal, the stock of iTeos Therapeutics, Inc. (NASDAQ: ITOS) has experienced a surge in value during the present trading session. At the latest market evaluation, ITOS shares demonstrated an increase of 46.31% on the US stock exchanges, reaching $17.83. Clinical Advancements: Promising Developments In GALAXIES Lung-201 ...
ITeos Therapeutics Up Over 46%, On Track for Record Percent Increase -- Data Talk
iTeos Therapeutics, Inc. (ITOS) is currently at $17.81, up $5.62 or 46.1% --Would be highest close since May 26, 2023, when it closed at $18.05 --Would be largest percent increase on record (Based o